Genome-wide association studies (GWAS) have laid the foundation for many downstream investigations, 39 including the biology of complex traits, drug development, and clinical guidelines. However, the dominance of European-40 ancestry populations in GWAS creates a biased view of human variation and hinders the translation of genetic 41 associations into clinical and public health applications. To demonstrate the benefit of studying underrepresented 42 populations, the Population Architecture using Genomics and Epidemiology (PAGE) study conducted a GWAS of 26 43 clinical and behavioral phenotypes in 49,839 non-European individuals. Using novel strategies for multi-ethnic analysis of 44 admixed populations, we confirm 574 GWAS catalog variants across these traits, and find 28 novel loci and 42 residual 45 signals in known loci. Our data show strong evidence of effect-size heterogeneity across ancestries for published GWAS 46 associations, which substantially restricts genetically-guided precision medicine. We advocate for new, large genome-47 wide efforts in diverse populations to reduce health disparities. 48
) Genetic data from ethnically 4 diverse populations will be crucial to powering genome-phenome association studies. Recent publications have reported 5 that some genetic predictors are restricted to certain ancestries, and thus may partially explain risk differences among 6 racial/ethnic groups. [4] [5] [6] [7] [8] [9] Additionally, as the field shifts its attention towards low frequency variants, which are more likely 7
to be population specific, we can no longer rely on the transferability of findings from one population to another, a 8 complication that has also been observed with some common variants. 10 ,11 9 The lack of representation of diverse populations in genetic research will exacerbate health disparities that exist 10 for many diseases. In the US, minority populations have a disproportionately higher burden of chronic conditions. 12 11 Globally, developing countries account for 89% of the world's population and 93% of the global disease burden. 13 By the 12 encouragement of diversity in genomics research, new opportunities for discovery will emerge, and the precision of 13 translational applications will improve. It is imperative that the research community rectifies the imbalance in 14 representation, not only because it is vital for precision medicine and translational research, but also because it is the right 15 thing to do. 16
Many factors contribute to this bias in genetic research, including the paucity of studies recruiting minorities, lack 17 of information and access to available studies, and complex statistical analyses required for multi-ethnic and admixed 18 study populations.
14 However, recent advancements in statistical analyses and genotyping technologies have lessened 19 many methodological concerns, removing barriers that had previously made researchers reluctant to recruit and analyze 20 heterogeneous samples. The Population Architecture using Genomics and Epidemiology (PAGE) study focuses on 21 exploring the genetics of underrepresented populations. 15, 16 In a study of 49,839 individuals of non-European ancestry, we 22 describe strategies for addressing challenges unique to multi-ethnic studies, investigate population bias in the current 23 GWAS literature, identify numerous new population-specific findings across 26 anthropometry, and behavior/lifestyle (smoking and coffee consumption). 36
Another major challenge in multi-ethnic studies is the limited availability of genotyping arrays that comparably tag 1 variation in multiple genetic ancestries, especially in those with African ancestry. To address this, a collaboration among 2 PAGE, Illumina, the Consortium on Asthma among African-ancestry Populations in the Americas (CAAPA) 17 , and other 3 academic partners developed the Multi-Ethnic Genotyping Array (MEGA), which includes a GWAS scaffold designed to 4 tag both common and low frequency variants in global populations.
18 (Extended Data Fig. 2 ) Additionally, it contains 5 enhanced tagging in exonic regions, hand-curated content to interrogate clinically relevant variants, and enriched 6 coverage to fine-map known GWAS loci. 19 The principles used to design MEGA are currently being used to create other 7 multi-ethnic genotyping arrays, including the Multi-Ethnic Global Array and the Global Screening Array. 8
Historically, analyses have been stratified by self-identified race/ethnicity to account for confounding by genetic 9
ancestry. In PAGE, we conducted principal component analysis to evaluate population substructure and mapped self-10 identified racial/ethnic groups onto the estimated principal components (PCs). Most notably in Hispanics/Latinos, but 11 evident to a lesser extent in all populations, genetic ancestry reveals greater demographic complexity compared with 12 culturally assigned labels, appearing as a continuum and demonstrating that genetic ancestry is not categorical in diverse 13 populations that have varying degrees of admixture (Figure 1) Multi-ethnic GWAS also require sophisticated statistical modeling. Known and cryptic relatedness are often 23 concerns for studies recruiting from smaller, more isolated populations. WHI, MEC, and BioMe used population-based 24 recruitment, whereas HCHS/SOL used a household sampling study design, which increased the inclusion of relatives. To 25 account for relatedness within and across studies, we used two recently developed analytical methods for GWAS of 26 related individuals from admixed populations. GENESIS 20-22 uses a linear mixed model and accounts for the correlation 27 among genetically similar samples through a kinship matrix that estimates the known and cryptic relatedness in the 28 presence of population structure and admixture. SUGEN 23 uses a modified version of generalized estimating equations 29 and creates "extended" families by connecting the households who share first degree relatives. Single-variant association 30 testing was completed in both GENESIS and SUGEN using phenotype-specific models that were adjusted by indicators 1 for study, self-identified race/ethnicity as a proxy for cultural background, phenotype-specific standard covariates, and the 2 first Supplementary Tables 2-3) . We attribute many of these discoveries to MEGA's globally diverse 12 panel of variants and to a study population that includes ancestries where these variants are more frequent. Here, we 13 briefly discuss two illustrative examples (Figure 2, Extended Data Fig. 3 ). 14 15 22 
23
A novel locus on chromosome 22q11 was associated with coffee intake (cups/day; Figure 2A rarity of the minor allele in Europeans, the discovery of this association was facilitated by our multi-ethnic study design 27 and driven by PAGE African Americans (P=3.70x10 -7 , N=11,862) and Hispanic/Latinos (P=3.21x10 -6 , N=15,837). The 28 ADORA2A gene is the main target of caffeine action in the central nervous system, and another SNP in this gene has 29 previously been associated with caffeine-induced sleep disturbance (rs4822498 24 ). This finding showcases an ancestry-30 specific genetic trait which impacts a behavioral phenotype. 31
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The second example describes a novel locus in CREB3L2/7q33 associated with total cholesterol levels 1 (rs73729087: P=1.52x10 -8 , N=33,185, CAF=0.05) (Figure 2B) . While rare in European populations (CAF=0.005), it is 2 more common in PAGE racial/ethnic groups, including African Americans (P=1.77x10 -6 , N=10,137, CAF=0.11) and 3 Hispanic/Latinos (P=2.58x10 -3 , N=17,802, CAF=0.02). This noncoding variant is located in the 3'-UTR, possibly 4 contributing to the regulation of CREB3L2 expression. These examples represent just two of numerous novel findings that 5
would not have been discovered in a European-descent study population. 6 Genetic Heterogeneity in the GWAS Catalog Reveals Need for Fine-Mapping 7
In general, GWAS identify loci where one or more tagSNPs show significant association with the trait of interest. 8
However, GWAS do not lead directly to the identification of the functional variant (fSNP), which ideally is in strong linkage 9 disequilibrium (LD) with the tagSNP(s) as surrogates. However, LD can vary among populations, so a tagSNP in perfect 10 LD with the fSNP in one population may be in weak LD in a different population. This can lead to inconsistent estimates of 11 the effect sizes among populations (and therefore effect size heterogeneity) if the tagSNP (instead of the causal fSNP) is 12 used for effect size calculations. Because European-descent individuals are overrepresented in GWAS discovery 13 populations and have different LD structures than other racial/ethnic groups, we hypothesized that effect size 14 heterogeneity among populations may exist for many previously reported tagSNP associations. 15
To test this hypothesis, we measured the frequency of effect heterogeneity in PAGE's multi-ethnic study 16 population of tagSNPs, primarily discovered in European populations, reported to the GWAS Catalog. We were able to 17
) a total of 574 tagSNPs in 261 distinct genomic regions across 26 traits out of the related 3,322 unique 18 Table 4) . 25 After Bonferroni correction for 574 tests, 132 tagSNPs (23.0%) 19 showed significant evidence of effect heterogeneity by genetic ancestry (SNPxPC P<8.71x10 -5 ). Thus, we observe that 20 nearly a quarter of reported GWAS Catalog tagSNPs, the preponderance of which were identified in European-based 21 studies, show evidence of effect heterogeneity upon replication in a multi-ethnic study population. This estimate is 22 conservative, because some of the effects that failed to replicate at P<5x10 -8 might have been underpowered to detect 23 heterogeneous effects, especially for the less frequent alleles. 24
GWAS Catalog variants (Supplementary
While we replicate 261 regions previously implicated in the GWAS Catalog, for most of these regions (77%) the 25 strongest signal was not the previously reported tagSNP from the GWAS Catalog but a different tagSNP. Additionally, 26 heterogeneity was only observed at 6% of these tagSNPs with the strongest associations within all 261 regions. This is 27 consistent with multi-ethnic analyses fine-mapping known association signals at a majority of reported GWAS catalog loci, 28 attributable to differential tagging of the underlying functional variation among populations, rather than that there are truly 29 differential underlying fSNP effect sizes. These results have important implications for precision medicine, as risk 30 prediction models based on heterogeneous GWAS Catalog tagSNPs could have poor accuracy in non-European 31 ancestries. 32 
Residual Signals in Known Loci Found in 26 Phenotypes

33
In addition to refining loci, multi-ethnic analysis affords an opportunity to identify independent signals (secondary 34 variants) within known loci, further enriching our understanding of the genetic architecture of traits. To test for secondary 35 Table 1, Supplementary Tables 2-3) . If the residual signal represents a statistically independent association, then we 3 would expect no net change in the strength of the association between unadjusted and adjusted models and that the 4 known tagSNPs were in weak LD with the residual SNPs. Out of the 42 residual variants, 23 and 25 in Hispanic/Latino 5 and African-descent populations, respectively, show evidence of a secondary association independent (LD r 2 <0.2) of 6 previously known loci. This analysis suggests that approximately half of these known loci, from majority European-based 7 GWAS, contain novel secondary signals in these populations. 8
To further illustrate the difference in mechanism between fine-mapping and secondary independent signals, we 9
highlight two examples (Figure 3) . The first is a refinement of the association between hexokinase 1 (HK1) and HbA1c. 10
The residual signal at rs72805692 (Punadj=9.22x10 -22 , N=11,178, CAF=0.061) is in moderate LD in European (r 2 =0.61) and 11
Hispanic/Latino (r 2 =0.63) populations with the previously implicated SNP (rs16926246) 5.7kb away. Therefore, after 12 adjustment, the signal is greatly diminished but remains statistically significant (Pcond=3.05x10 -9 ). This represents the 13 refinement of a known locus (fine-mapping), as the high LD present in this area results in an attenuated, but still 14 statistically significant, signal, and may represent only one underlying fSNP. In contrast, we found a residual signal for PR 15 interval at rs1895595, upstream of TBX5 (Punadj=2.16x10 -11 , N=17,428, CAF=0.17). After adjustment for 5 known tagSNPs 16 in this region (rs3825214, rs7312625, rs7135659, rs1895585, rs1896312), the signal remains largely unchanged 17
). This secondary signal at rs1895595 is independent of all 5 conditioned SNPs, with extremely low LD 18 To tease apart the influence of specific ancestral components on the 28 novel and 42 residual loci, we calculated 15 the correlation between the risk allele and each of the first ten PCs in the full PAGE sample (Figure 4A ). These 16 correlations reveal population structure underlying many of our novel and residual findings, in which there are population 17 differences in allele frequencies for the risk alleles. Most notably, the risk allele for a novel finding for cigarettes per day 18 among smokers on chromosome 1 (rs182996728; P=3.1x10 -8 ) was found to show significant correlation with PC4, which 19
represents Native Hawaiian/Pacific Islander ancestry. While this variant is monomorphic or rare in most populations, it is 20 found at 17.2% within our Native Hawaiian participants. An additional example is shown with the 5 novel and residual loci 21 highly correlated with PC6 which are related to height and found to be at higher frequencies in 1000 Genomes within a 22 subgroup of populations within East Asia, such as Japanese or Vietnamese. The observed variability in allele frequency 23
for our findings will result in differential impacts across populations and must be considered when building risk prediction 24 models. That our findings exhibit substantial variability in allele frequencies further illustrates a need for the inclusion of 25 diverse populations disproportionately affected by disease. 26 
27
. Not only has the genetic diversity of PAGE improved characterization of previously known associations and 8 enabled the discovery of novel genetic associations, but it has also provided population-specific allele frequencies for 9 clinically relevant variants (CRVs) that will have immediate impact on clinical care. MEGA was designed to include CRVs 10 from well-known and frequently used knowledge bases. 19 A finding within our analyses shows an association between 11 HBB (rs334) and HbA1c levels (Pcond=6.87x10 Hemoglobin genetic variants are also known to affect the performance of some HbA1c assays [29] [30] [31] , potentially leading 17 practitioners to incorrectly believe that a patient has achieved glucose control. This conclusion leaves the patient more 18 susceptible to type II diabetes (T2D) complications. Alternative long-term measures of glucose control that are not 19 impacted by hemoglobin variants, such as the fructosamine test, should be considered for sickle cell carriers being 20 evaluated for T2D. This result illustrates how ancestry-specific findings may be transferable to other groups that share the 21 same genetic ancestry, such as, in this case, the African ancestry present in both African Americans and some 22
Hispanic/Latinos. 23 We also investigated the HLA-B*57:01 haplotype, which interacts with the HIV drug abacavir to trigger a 24 potentially life-threatening immune response in 5-8% of patients. [32] [33] [34] The FDA recommends screening all patients for 25
HLA-B*57:01, prior to starting abacavir treatment. 35 The rs2395029 variant in HCP5, a near perfect tag of HLA-B*57:01, 26 is used to screen for abacavir hypersensitivity. 36 Using PAGE and Global Reference Panel samples, we show that risk 27 allele (T) frequencies for rs2395029 rise above 5% in multiple large South Asian populations, and rise above 1% within 28 some, but not all, admixed populations with Native American ancestry ( Figure 5) . Thus, the population attributable risk for 29 this variant varies between continental populations and also within sub-continental regions. The allele frequencies from 30 PAGE for clinically relevant variants, particularly polymorphisms with a medical guideline, will be available through several 31 online databases, including ClinGen and dbSNP, to further help researchers and clinicians identify at-risk groups. PAGE 32 allele frequencies can therefore aid in expanding the reach of precision medicine to encompass individuals of diverse 33 ancestry. 34
. Using a multi-ethnic study with the novel MEGA product and methods for analyzing admixed populations, we 10 provide empirical evidence supporting theoretical concerns regarding the European-centric bias in GWAS. To our 11 knowledge, this is the first time effect heterogeneity in the GWAS Catalog has formally been assessed, and the 12 observation that a quarter of GWAS Catalog tagSNPs show evidence of effect heterogeneity by genetic ancestry has 13 profound implications for precision medicine. Furthermore, our results suggest that a majority of GWAS catalog 14 associations are fine-mapped in a multi-ethnic population, consistent with differential LD between tagSNP and functional 15 variant across populations. It is imperative that clinically relevant variants are validated in diverse populations to prevent 16 the use of imprecise genetic tags in clinical applications. Genetic tests are already being used to guide clinical decisions, 17 and efforts to develop polygenic risk prediction models are currently underway. Researchers need to be aware of the 18 limitations of tagSNPs that have not been replicated in non-European populations.
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This study also provides evidence that a significant number of novel loci (as well as independent, secondary 20 alleles in known loci) relevant to non-European ancestries remain to be identified, many of which are undiscoverable in 21
European-only study populations due to low allele frequencies in Europeans. Cumulatively, these results expose several 22
shortcomings that arise from an overreliance on European GWAS. 23
The findings from this research demand a reevaluation of how future genetic studies are designed and 24
implemented. As next-generation sequencing, precision medicine, and direct-to-consumer genetic testing become more 25 common, it is critical that the genetics community takes a forward-thinking approach towards research in diverse 26 populations. The increasing ability to identify rare variants further highlights the necessity to study genetically diverse 27 .
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The copyright holder for this preprint (which was not . http://dx.doi.org/10.1101/188094 doi: bioRxiv preprint first posted online Sep. 15, 2017; populations, as rare variation is more likely to be ancestry specific. The All of Us Research Program embraces the reality 1 that the success of precision medicine requires precision genomics and therefore emphasizes the recruitment and active 2 participation of underrepresented minorities 39 . It is in the best interest of our research community to follow suit and take 3 steps to become more inclusive. As world populations become increasingly diverse 40, 41 , geneticists and clinicians will be 4 required to evaluate genetic predictors of complex traits in non-Europeans. Our current genomic databases are not 5 representative of populations with the greatest health burden or that will ultimately benefit from this work. This realization, 6 combined with the increased availability of resources for studying diverse populations, means that researchers and 7 funders can no longer afford to ignore non-European populations. This study provides evidence and motivation to make 8 research in diverse populations a priority in the field of genetics. 9
. that passed initial quality control at CIDR were released to the Quality Assurance / Quality Control (QA/QC) analysis team 35 at the University of Washington Genetics Coordinating Center (UWGCC). The UWGCC further cleaned the data 36 according to previously described methods 42 , and returned genotypes for 51,520 subjects. A total of 1,705,969 SNPs 37 were genotyped on the MEGA. Quality Control of genotyped variants was completed by filtered through various criteria, 38 including the exclusion of (1) CIDR technical filters, (2) variants with missing call rate >= 2%, (3) variants with more than 6 39 discordant calls in 988 study duplicates, (4) Imputation. In order to increase coverage, and thus improve power for fine-mapping loci, all PAGE individuals who were 46 successfully genotyped on MEGA were subsequently imputed into the 1000 Genomes Phase 3 data release 43 .
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Imputation was conducted at the University of Washington Genetic Analysis Center (GAC). Genotype data which passed 48 the above quality control filters was phased with SHAPEIT2 44 and imputed to 1000 Genomes Phase 3 reference data 49 using IMPUTE version 2.3.2
45
. Segments of the genome which were known to harbor gross chromosomal anomalies 50 were filtered out of the final genotype probabilities files. Imputed sites were excluded if the IMPUTE info score was less 51 than 0.4. A total of 39,723,562 imputed SNPs passed quality control measures. (See Supplemental Methods) 52 53
Principal Component Analysis. The selection of unrelated individuals was essential for accurate estimation of the 54 principal components within the global study population. Kinship coefficients were estimated using PC-Relate, as 55 implemented in the R package GENESIS 20, 21 . The SNPRelate 46 package was implemented in R for principal components 56
segments connecting his or her PC values. The amount of variance explained diminished with each subsequent PC, and 4 we estimated that the top 10 PCs provided sufficient information to explain the majority of genetic variation in the PAGE 5 study population. 6 7
Genome-Wide Association Testing. All imputed autosomal variants with IMPUTE info score >0.4 (n=39,723,562) were 8 eligible for association testing in phenotype-specific models. An effective sample size (effN) was calculated for each SNP 9 in a given phenotype-specific model, where effN = 2*MAF*(1-MAF)*N*info, where MAF is the minor allele frequency 10 among the set of individuals included in a phenotype-specific model, N is the total sample size for a given phenotype, and 11 info is the SNP's IMPUTE info score. Variants with an effN less than 30 (continuous phenotypes) or 50 (binary 12 phenotypes), were excluded from the final set of phenotype-specific results. QQ plots and lambdaGC were used to assess 13 genomic inflation in all phenotypes, for which lambdas ranged from 0.98 to 1.15. Single-variant association testing for 14 each phenotype used an additive model that was adjusted by indicators for study, self-identified race/ethnicity, the first 10 15
PCs, and phenotype-specific covariates. residual findings are included in Supplementary Table 3.  1  2 Assessing Single-Variant Results. SUGEN association results were used for the identification of novel and residual 3 findings for all phenotypes. The variant with the smallest p-value in a 1Mb region was considered the "lead SNP". A lead 4 SNP was considered to be a novel loci if it met the following criteria: 1) the lead SNP was located greater than +/-500 Kb 5 away from a previously known loci (per the phenotype-specific known loci list); 2) had a SUGEN p-value less than 5x10 -8 ; 6
3) had a SUGEN conditional p-value less than 5x10 -8 after adjustment for all previously known loci on the same 7 chromosome; and 4) had 2 or more neighboring SNPs (within +/-500 Kb) with a p-value less than 1x10 -5 . A lead SNP was 8 considered to be a residual signal in a previously known loci if it met the following criteria: 1) the lead SNP was located 9 within +/-500 Kb of a previously known loci; 2) had a SUGEN p-value less than 5x10 -8 ; and 3) had a SUGEN conditional 10 p-value less than 5x10 -8 after adjustment for all previously known loci on the same chromosome. Full results for all novel 11 and residual findings are included in Supplementary 
